Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

References for PMC Articles for PubMed (Select 20067423)


Racial disparities in HIV virologic failure: do missed visits matter?

Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JH, Raper JL, Wray NP, Cole SR, Schumacher JE, Davies S, Saag MS.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):100-8. doi: 10.1097/QAI.0b013e31818d5c37.


Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

Chandwani A, Shuter J.

Ther Clin Risk Manag. 2008 Oct;4(5):1023-33.


Missed visits and mortality among patients establishing initial outpatient HIV treatment.

Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, Abroms S, Raper JL, Saag MS, Allison JJ.

Clin Infect Dis. 2009 Jan 15;48(2):248-56. doi: 10.1086/595705.


Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial.

Hansen AB, Gerstoft J, Kirk O, Mathiesen L, Pedersen C, Nielsen H, Jensen-Fangel S, Sørensen HT, Obel N.

J Clin Epidemiol. 2008 Jan;61(1):87-94. Epub 2007 Aug 3.


The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy.

Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):194-201.


HIV-infected African Americans are willing to participate in HIV treatment trials.

Garber M, Hanusa BH, Switzer GE, Mellors J, Arnold RM.

J Gen Intern Med. 2007 Jan;22(1):17-42.


External validity of clinical trials in acute myocardial infarction.

Steg PG, López-Sendón J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F; GRACE Investigators.

Arch Intern Med. 2007 Jan 8;167(1):68-73.


Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care.

Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):411-6.


Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

JAMA. 2006 Aug 16;296(7):769-81.


Efficacy vs effectiveness trial results of an indicated "model" substance abuse program: implications for public health.

Hallfors D, Cho H, Sanchez V, Khatapoush S, Kim HM, Bauer D.

Am J Public Health. 2006 Dec;96(12):2254-9. Epub 2006 Jun 29.


Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.

Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ, Bertrand ME, Mercado N, Boersma E; EHS-CR Investigators.

Eur Heart J. 2006 Mar;27(6):671-8. Epub 2006 Jan 19.


Are racial and ethnic minorities less willing to participate in health research?

Wendler D, Kington R, Madans J, Van Wye G, Christ-Schmidt H, Pratt LA, Brawley OW, Gross CP, Emanuel E.

PLoS Med. 2006 Feb;3(2):e19. Epub 2005 Dec 6. Review.


Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.

Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):324-8.


Duration of highly active antiretroviral therapy regimens.

Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Saag MS.

Clin Infect Dis. 2003 Sep 1;37(5):714-22. Epub 2003 Aug 13.


A review of low-dose ritonavir in protease inhibitor combination therapy.

Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW.

Clin Infect Dis. 2003 Jun 15;36(12):1585-92. Epub 2003 Jun 5. Review.


Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.

Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, Wyen C, Schmitz K, Sauerbruch T, Rockstroh JK.

Eur J Med Res. 2003 Feb 21;8(2):56-60.


Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry.

Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald E; TIMI 9 Trial and TIMI 9 Registry. Thrombolysis In Myocardial Infarction.

Am Heart J. 2003 Jan;145(1):109-17.


Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration.

Lancet. 2002 Jul 13;360(9327):119-29. Erratum in: Lancet 2002 Oct 12;360(9340):1178.


Participation in research and access to experimental treatments by HIV-infected patients.

Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, Shapiro MF, Bozzette SA; HIV Cost and Services Utilization Study Consortium.

N Engl J Med. 2002 May 2;346(18):1373-82.


Principles of effectiveness trials and their implementation in VA Cooperative Study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder'.

Bauer MS, Williford WO, Dawson EE, Akiskal HS, Altshuler L, Fye C, Gelenberg A, Glick H, Kinosian B, Sajatovic M.

J Affect Disord. 2001 Dec;67(1-3):61-78.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk